Results 81 to 90 of about 34,942 (245)
British Journal of Clinical Pharmacology, EarlyView.After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon +11 more
wiley +1 more source
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine [PDF]
, 2009 Peter Avery, Shaymaa S Mousa, Shaker A MousaThe Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USAAbstract: Advances in genotype technology in the last decade have put the pharmacogenomics revolution at the
Peter Avery +2 more
core
Addressing Ancestry and Sex Bias in Pharmacogenomics [PDF]
The association of an individual's genetic makeup with their response to drugs is referred to as pharmacogenomics. By understanding the relationship between genetic variants and drug efficacy or toxicity, we are able to optimize pharmacological therapy ...
Corpas, Manuel +5 more
core +1 more source
Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications
British Journal of Clinical Pharmacology, EarlyView.Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba +2 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire +3 more
wiley +1 more source
The pharmacogenomics of pain management: prospects for personalized medicine [PDF]
, 2016 Sonya Ting,1 Stephan Schug2,3 1Department of Anaesthesia, Sir Charles Gairdner Hospital, Perth, WA, Australia; 2Anaesthesiology Unit, School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia; 3Department of Anaesthesia ...
Ting S, Schug S
core
Pharmacogenomics in the Evaluation of Efficacy and Adverse Events During Clinical Development of Vaccines [PDF]
, 2008 The understanding of vaccine-induced immune responses in adults and infants is limited. Current vaccination schedules for infants are frequently debated. Especially, the relationship among the timing, the frequency of the dosing, and the generation of an
Nilsson, Lennart, +4 more
core +1 more source
Chronic Diseases and Translational Medicine, EarlyView.Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig +7 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples +10 more
wiley +1 more source